{
    "symbol": "CLBS",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-05 23:29:07",
    "content": " Simultaneously with the signing of the merger agreement last week, Caladrius also entered into collaboration and investment agreements with Send, whereby we made a $10 million investment in send and created a development collaboration structure, including a joint steering committee, from which we will be providing human resources over the course of the next several months leading up to the closing in order to maintain the momentum associated with the development of the exciting products in the Sand pipeline. Research and development activities in the current year period focused on the advancement of our ischemic repair platform and related to expenses associated with efforts to continue execution and acceleration of enrollment of the FREEDOM trial and Expenses associated with the planning, preparation and initiation of the Phase Ib proof-of-concept trial for CLBS-201 as a treatment for diabetic kidney disease and ongoing expenses for HONEDRA in critical limb ischemia and burgers disease in Japan associated with study closeout activities and preparation for the preconsultation meetings with the PMDA. As of March 31, 2022, the company had cash, cash equivalents and marketable securities of approximately $88.5 million, which positions us well relative to the projected capital obligations for our existing development programs as well as our cash and investments balance target at the time of closing of the merger with Sen. That completes the financial overview."
}